Concerning STAT-3 expression in DLBCL, it was related to concurrent downregulation of BCL-6 and MYC, which leads to STAT-3 activation, especially those with the DLBCL-NGCB subtype [16,19]. This evidence concerns the gene BCL6 and diffuse large B-cell lymphoma.